Get the Stockscreener App
16.11
13.53%
-2.52
Pre-market:
16.50
0.39
+2.42%
Bioage Labs Inc stock is traded at $16.11, with a volume of 853.94K.
It is down -13.53% in the last 24 hours and down -25.28% over the past month.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
See More
Previous Close:
$18.63
Open:
$18.49
24h Volume:
853.94K
Relative Volume:
1.23
Market Cap:
$672.63M
Revenue:
$5.92M
Net Income/Loss:
$-75.79M
P/E Ratio:
-7.6203
EPS:
-2.1141
Net Cash Flow:
$-59.15M
1W Performance:
-24.08%
1M Performance:
-25.28%
6M Performance:
+203.39%
1Y Performance:
+254.85%
1-Day Range:
$15.68
$18.71
1-Week Range:
$15.68
$21.09
52-Week Range:
$2.88
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
Name
Bioage Labs Inc
Sector
Phone
510-806-1445
Address
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
16.11 | 672.63M | 5.92M | -75.79M | -59.15M | -2.1141 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | Oppenheimer | Outperform |
| Feb-18-26 | Upgrade | Jefferies | Hold → Buy |
| Jan-27-26 | Initiated | Piper Sandler | Overweight |
| Dec-05-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-22-25 | Upgrade | Citigroup | Neutral → Buy |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Dec-10-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-09-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-21-24 | Initiated | Citigroup | Buy |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-21-24 | Initiated | Morgan Stanley | Overweight |
View All
Bioage Labs Inc Stock (BIOA) Latest News
Oppenheimer reiterates Outperform on BioAge Labs stock at $60 By Investing.com - Investing.com India
Jefferies reiterates Buy on BioAge Labs stock citing NLRP3 progress By Investing.com - Investing.com India
Chipmakers Recap: Can BioAge Labs Inc lead its sector in growth2026 WrapUp & Technical Confirmation Alerts - baoquankhu1.vn
Jefferies reiterates Buy on BioAge Labs stock citing NLRP3 progress - Investing.com
BioAge Labs (NASDAQ: BIOA) registers shelf for future equity and debt offers - Stock Titan
BioAge Labs Full-Year 2025 Net Loss Narrows - Moomoo
BioAge Labs (NASDAQ:BIOA) Stock Price Down 9.8%Here's Why - MarketBeat
BioAge Labs Provides Business Updates - Lifespan Research Institute
BioAge Labs Reports Positive 2025 Financial Results and Advances BGE-102 NLRP3 Inhibitor Toward Phase 2 Trials in Cardiovascular and Ophthalmology Indications - Minichart
BioAge Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
BioAge Labs 2025-2026 Pipeline: Advancing BGE-102 NLRP3 Inhibitor for Cardiometabolic Disease and Ophthalmology Based on Aging Biology Insights - Minichart
BioAge Highlights BGE-102 Progress and Financial Strength - TipRanks
BIOAGE Labs Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioAge Labs (NASDAQ: BIOA) boosts R&D and outlines cash runway to 2029 - Stock Titan
Earnings Flash (BIOA) BioAge Labs Posts 2025 Collaboration Revenue $9M, vs. FactSet Est of $7.1M - marketscreener.com
Earnings Flash (BIOA) BioAge Labs Posts 2025 Net Loss $2.24 a Share, vs. FactSet Est of $1.89 Loss - marketscreener.com
BioAge Labs (NASDAQ: BIOA) widens 2025 loss but extends cash runway to 2029 - Stock Titan
BioAge says oral drug cut a heart-risk marker 86% in Phase 1 - Stock Titan
BioAge Labs, Inc.(NasdaqGS: BIOA) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Certain Warrant of BioAge Labs, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - marketscreener.com
Certain Common Stock of BioAge Labs, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - marketscreener.com
BioAge Labs, Inc.: Fundamental Analysis and Financial Ratings | Y7G | US09077V1008 - marketscreener.com
If You Invested $1,000 in BioAge Labs Inc. (BIOA) - Stock Titan
Jefferies upgrades BioAge Labs (BIOA) - MSN
BioAge Labs (NASDAQ:BIOA) Trading Down 5.9%What's Next? - MarketBeat
BioAge Makes a Comeback, Yet Technical Indicators Lean Bearish - Bitget
Can BioAge Labs Inc expand its profit marginsMarket Performance Summary & Pattern Based Trade Signal System - baoquankhu1.vn
BioAge Labs (NASDAQ:BIOA) Shares Up 8.8%Should You Buy? - MarketBeat
BIOAGE Labs Inc expected to post a loss of 74 cents a shareEarnings Preview - TradingView
BioAge Labs, Inc. (NASDAQ:BIOA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Quarterly Recap: Will BioAge Labs Inc outperform small cap indexesTrade Volume Summary & Daily Entry Point Alerts - baoquankhu1.vn
BioAge Labs (NASDAQ:BIOA) Given New $52.00 Price Target at Citigroup - MarketBeat
Aug Update: Will BioAge Labs Inc outperform small cap indexesEarnings Recap Report & Smart Swing Trading Techniques - baoquankhu1.vn
Bioage Labs Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
BioAge Labs (BIOA) price target increased by 24.14% to 12.24 - MSN
Market Trends: How does BioAge Labs Inc perform in inflationary periodsTrade Volume Report & Entry and Exit Point Strategies - baoquankhu1.vn
BioAge Investors Lose Last Bid At Obesity Drug-Linked Suit - Law360
BioAge Labs (NASDAQ: BIOA) CMO exercises options, sells 7,433 shares in 10b5-1 trade - Stock Titan
[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan
BioAge Labs (NASDAQ:BIOA) Shares Gap DownHere's Why - MarketBeat
BIOA (NASDAQ: BIOA) insider files Form 144 showing multiple sales - Stock Titan
Risk Analysis: How does BioAge Labs Inc perform in inflationary periods2025 Performance Recap & Community Driven Trade Alerts - baoquankhu1.vn
Investment Recap: How do insiders feel about BioAge Labs Inc2025 Geopolitical Influence & Weekly High Return Stock Opportunities - baoquankhu1.vn
BIOA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update - MarketBeat
The Gross Law Firm Notifies Shareholders of BioAge Labs, Inc.(BI - GuruFocus
BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion - Yahoo Finance
Oppenheimer Begins Coverage on BioAge Labs (NASDAQ:BIOA) - MarketBeat
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Oppenheimer Initiates Coverage of BioAge Labs (BIOA) with Outperform Recommendation - Nasdaq
BioAge Labs: Differentiated NLRP3 Inhibitor BGE-102 Positions Company for Best-in-Class Cardiometabolic Upside and Strategic M&A Appeal - TipRanks
Bioage Labs Inc Stock (BIOA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):